
Intravitreal Bevacizumab for Treatment of Refractory Central Serous Choroidoretinopathy
- Morteza Entezari Alireza Ramezani Mehdi Yaseri
- 대한안과학회
- The Korean Journal of Ophthalmology
- Vol.26 No.2
- 등재여부 : KCI등재
- 2012.04
- 139 - 142 (4 pages)
In a clinical case series, 5 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 1 year received one intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a through ophthalmic examination 1 day, 1 week, and 1, 2, and 6 months after the injection. Best corrected visual acuity (BCVA) and central macular thickness were compared before and after treatment by optical coherence tomography. Mean BCVA was improved significantly (p = 0.020) from 0.60 ± 0.25 to 0.50 ± 0.18 and 0.29 ± 0.19 logarithm of minimum angle of resolution at 6 and 18 weeks, respectively. Central macular thickness was also decreased significantly (p = 0.010) from 370 ± 65 to 208 ± 23 μm at 4 months. No recurrence was occurred during follow-up. IVB injection may have beneficial effect in the treatment of refractory CSC.
Case Report
Discussion
Conflict of Interest
References